Flaviviridae infectious disease

Researchers are testing a new dengue vaccine called VLPDEN-02 in 42 healthy adults who have never had a flavivirus infection. The vaccine combines four virus-like particles, one for each dengue virus type, with an adjuvant to boost the immune response. Participants receive three …

This study tests whether a two-dose regimen of the Butantan-DV dengue vaccine, given nine months apart, produces a stronger immune response than a single dose in children and adolescents aged 2 to 17 who have never had dengue. The trial also checks that the vaccine made at a new …

This Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune re…

This large study tests several treatments in people hospitalized with moderate or severe dengue. The goal is to find safe, affordable drugs that prevent the disease from getting worse and help patients recover faster. Over 8,800 participants across multiple sites will be enrolled…

This study will collect blood samples from 200 people aged 12 and older who either have or do not have dengue. The goal is to use these samples to develop and improve diagnostic tests for dengue. Participants must have symptoms consistent with dengue and cannot have been vaccinat…

This study tests whether a 20-session exercise program can improve muscle strength, reduce fatigue, and help with balance in people who had dengue or chikungunya in the last five years. Fifty-four adults will do supervised aerobic, strength, and breathing exercises twice a week. …

This observational study follows 235 people hospitalised with dengue in Vietnam to map how the illness unfolds, especially the leaking of blood vessels that can lead to severe disease. Researchers will collect routine clinical data, blood samples, and ultrasound scans during the …